China Proposes Up to 6 Years of Clinical Trial Data Exclusivity in Draft Measures
核心洞察
China's National Medical Products Administration (搜索) (NMPA) has released draft measures proposing up to 6 years of clinical trial data exclusivity for innovative drugs, with reduced periods for drugs already approved overseas.
The draft Implementation Measures would grant 3-year protection periods for improved new drugs and first-approved generic drugs of products marketed overseas but not in China, creating a tiered exclusivity system.
The proposed regulations require applicants to apply for data protection simultaneously with drug marketing authorization applications, with public comments being accepted until May 18, 2025.
China's National Medical Products Administration (搜索) (NMPA) has released draft measures that would establish a comprehensive framework for protecting clinical trial data, potentially granting pharmaceutical innovators up to six years of data exclusivity. The proposal, announced on March 19, 2025, represents a significant development in China's pharmaceutical regulatory landscape.
Proposed Data Protection Framework
The draft "Implementation Measures for the Protection of Drug Trial Data" and accompanying "Working Procedures" outline a tiered system of data exclusivity periods based on drug classification. Under the proposed measures, innovative drugs would receive the highest level of protection—six years from the date of their first domestic marketing authorization.
For innovative drugs already marketed overseas, the protection period would be reduced by the time difference between overseas approval and Chinese application acceptance. This calculation method effectively incentivizes simultaneous global development and faster entry into the Chinese market.
Dr. Li Wei, pharmaceutical policy expert at Beijing Medical University (搜索), explains: "These measures aim to strike a balance between encouraging innovation and ensuring timely access to medications. The sliding scale for overseas-approved drugs reflects China's desire to reduce delays in bringing global innovations to Chinese patients."
The draft measures define protected data as undisclosed trial information submitted in complete application materials for first-time drug marketing authorization in China. Notably, the protection covers all test data used to demonstrate safety, efficacy, and quality.
Tiered Protection System
The proposed framework establishes different protection periods based on drug classification:
- Innovative drugs: 6 years maximum
- Improved new drugs: 3 years maximum
- First approved generic drugs of products marketed overseas but not in China: 3 years
For drugs with multiple indications under the same approval number, each indication would receive data protection according to its registration category. The scope of protection for newly added indications would cover the clinical trial data supporting that specific indication.
"This tiered approach recognizes different levels of innovation and investment," notes Sarah Johnson, regulatory affairs director at PharmGlobal Consulting (搜索). "By providing meaningful protection periods for different categories, China is acknowledging the value of both breakthrough innovations and incremental improvements."
Application Process and Enforcement
The draft measures stipulate that applicants must submit data protection applications simultaneously with their drug marketing authorization applications. For approved drugs meeting data protection conditions, the NMPA would mark protection information on the drug approval certificate and publish relevant details on the Center for Drug Evaluation (搜索) website.
During the protection period, the NMPA would not approve marketing applications from other applicants that rely on the protected data without the holder's consent. However, applications based on independently obtained data would still be permitted.
Generic manufacturers could submit applications relying on protected data within one year before the expiration of the data protection period. The Drug Evaluation Center (搜索) would complete technical reviews but suspend final approval until after the protection period expires.
Industry Implications
The proposed measures represent a significant step in China's efforts to align with international standards while maintaining distinctive features tailored to domestic priorities.
Industry analysts note that the 6-year maximum protection period for innovative drugs positions China between the United States (which generally provides 5 years) and Europe (which offers 8-10 years of combined data and market protection).
"These measures signal China's commitment to pharmaceutical innovation while maintaining its own approach to balancing innovation and access," says Michael Chen, pharmaceutical industry analyst at Asia Health Markets (搜索). "The provisions for reduced protection periods for drugs already approved overseas clearly aim to accelerate global innovations reaching Chinese patients."
For multinational pharmaceutical companies, the draft measures create both opportunities and challenges. While establishing clearer protection for clinical data, the reduction in exclusivity periods for drugs already approved overseas may pressure companies to include China earlier in global development plans.
Comparison to Previous Regulations
The 2019 Implementation Regulations of China's Drug Administration Law had previously established the concept of data exclusivity but lacked detailed implementation mechanisms. The current draft measures provide the procedural framework that has been missing since then.
The draft expands protection beyond new chemical drugs to include biologics and improved drugs, representing a more comprehensive approach than earlier regulations.
Public Comment Period
The NMPA is accepting public comments on the draft measures until May 18, 2025. Industry stakeholders, including domestic and international pharmaceutical companies, are expected to provide feedback on various aspects of the proposal.
Key areas likely to receive attention include the definition of "undisclosed" data, the calculation method for protection periods of overseas-approved drugs, and the procedures for resolving disputes over data protection claims.
Future Outlook
If implemented, these measures would establish one of the most detailed clinical data protection systems in Asia. The final regulations could significantly influence pharmaceutical development strategies, particularly for companies considering when and how to enter the Chinese market.
The measures align with broader Chinese policy goals of encouraging pharmaceutical innovation while ensuring that protection periods do not unduly delay generic competition. The balanced approach reflects China's evolving position in the global pharmaceutical landscape—increasingly focused on fostering domestic innovation while remaining open to global advances.
As the comment period progresses, the final shape of these regulations will be closely watched by pharmaceutical companies, healthcare providers, and patients alike.